Takeda Pharmaceutical (TAK) Free Cash Flow Growth (1y) (2019 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Free Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 1,829.52% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 58.76% |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | -37.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.45% |
| Mar 31, 2026 | -56.60% |
| Dec 31, 2025 | -4.43% |
| Sep 30, 2025 | 208.50% |
| Jun 30, 2025 | 24.40% |
| Mar 31, 2025 | -18.55% |
| Dec 31, 2024 | 115.45% |
| Sep 30, 2024 | -55.65% |
| Jun 30, 2024 | 44.91% |
| Mar 31, 2024 | 125.02% |
| Dec 31, 2023 | -55.07% |
| Sep 30, 2023 | -11.19% |
| Jun 30, 2023 | 3.32% |
| Mar 31, 2023 | -44.39% |
| Dec 31, 2022 | -11.57% |
| Sep 30, 2022 | 134.60% |
| Jun 30, 2022 | -45.62% |
| Mar 31, 2022 | -57.81% |
| Dec 31, 2021 | 41.98% |
| Sep 30, 2021 | -6.92% |